THE POWER OF REVERSIBLE PROTEASOME INHIBITION

prescription pharmaceutical preparations for use in the diagnosis or treatment of human diseases and disorders, namely, oncologic diseases and disorders, excluding analgesics

research services, namely, research, development, validation, testing, data analysis and product development services in the biomedical, genomic, pharmacogenomic, diagnostic, clinical trial design, and biotechnology fields; research consulting services, namely, research, development, validation, testing, data analysis, and product development services for others in the biomedical, genomic, pharmaceutical, pharmacogenomics, diagnostic, clinical trial design, and biotechnology fields; consultation services, namely, providing consultation to others via global, national, and local computer networks in the fields of life sciences, pharmacogenomics, diagnostics, clinical trial design and biotechnology; providing on-line computer databases via global, national, and local computer networks in the fields of life sciences, pharmacogenomics, diagnostics, clinical trial design and biotechnology

medical services and medical diagnostic services, namely, diagnosing, preventing, and predicting disease, identifying hereditary risk factors, diagnostic testing, prognostic testing, gene and protein testing, identifying physiological characteristics, establishing individual preventative programs, establishing disease treatment based on gene and protein expression and/or activity, evaluating clinical trial progress, drug monitoring and computer tracking of a patient's health progress